Knight Therapeutics (TSX:GUD) announced the Canadian launch of Titan Pharmaceuticals’ (NASDAQ:TTNP) Probuphine subdermal implant of buprenorphine hydrochloride for the management of opioid dependence in patients clinically stabilized on no more than 8 mg. of sublingual buprenorphine.
“The approval of Probuphine by Health Canada earlier this year was a milestone and we look forward to supporting our partner Knight Therapeutics in this next phase,” Titan president and CEO, Sunil Bhonsle, said in a statement.
“The commercial launch of Probuphine provides the Canadian medical community with a novel, long-term treatment alternative that can provide benefits to many patients suffering from this disease,” he added.
Probuphine is the only subdermal implant designed to deliver buprenorphine continuously for six months following a single treatment.
